期刊
EUROPEAN NEUROPSYCHOPHARMACOLOGY
卷 20, 期 8, 页码 562-567出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.euroneuro.2010.02.004
关键词
Antidepressant; Placebo; Discontinuation; Major; Depressive; Disorder; Adults
资金
- Bristol-Myers Squibb Company
- Forest Pharmaceuticals
- National Institute of Mental
- Abbott Laboratories
- Alkermes
- Aspect Medical Systems
- Astra-Zeneca
- Bio Research
- Brain Cells, Inc.
- Cephalon
- Clinical Trial Solutions
- Eli Lilly Et Company
- Forest Pharmaceuticals Inc.
- Ganeden
- GlaxoSmithKline
- J & J Pharmaceuticals
- Lichtwer Pharma GmbH
- Lorex Pharmaceuticals
- NARSAD
- NCCAM
- NIDA
- NIMH
- Novartis
- Organon Inc.
An increased likelihood of receiving placebo in randomized clinical trials has been found to predict greater chances of trial success. However, patients who are less likely to receive active therapy (and more likely to receive placebo) may be at increased risk of attrition which, in turn, can limit the statistical power of a study. Therefore, in the present work, we sought to investigate the relationship between the probability of receiving placebo and the likelihood of prematurely discontinuing treatment. Medline/Pubmed publication databases were searched for RCT in MDD. A meta-regression established that the likelihood of receiving placebo did not predict either antidepressant discontinuation rates, placebo-discontinuation rates or the risk ratio of discontinuing antidepressants versus placebo. An increased likelihood of receiving placebo did not inflate discontinuation rates which did not influence the degree of antidepressant-placebo separation. (C) 2010 Elsevier B.V. and ECNP. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据